Nonhormonal treatments for heavy menstrual bleeding

Journal of Women's Health

Volumn 20, Issue 11, 2011, Pages 1645-1653

  Edlund, Måns ^a  

^a DANDERYD HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOMETHYLCYCLOHEXANECARBOXYLIC ACID 1 [(ETHOXYCARBONYL)OXY]ETHYL ESTER; AMINOCAPROIC ACID; DESMOPRESSIN; ETAMSYLATE; FLURBIPROFEN; HEMOSTATIC AGENT; IBUPROFEN; MEFENAMIC ACID; NAPROXEN; TRANEXAMIC ACID; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANXIETY; ARTICLE; BACKACHE; BLEEDING; BODY WEIGHT; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSMENORRHEA; DYSPEPSIA; FATIGUE; FLUID RETENTION; GASTROINTESTINAL DISEASE; HEADACHE; HOT FLUSH; HUMAN; HYPONATREMIA; MENORRHAGIA; METEORISM; MULTIPLE CYCLE TREATMENT; NAUSEA; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; SIDE EFFECT; STANDING; SYNCOPE; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIFIBRINOLYTIC AGENTS; CLINICAL TRIALS AS TOPIC; FEMALE; HEMOSTATICS; HUMANS; MENORRHAGIA; QUALITY OF LIFE; TRANEXAMIC ACID;

EID: 81155123275     PISSN: 15409996     EISSN: 1931843X     Source Type: Journal    
DOI: 10.1089/jwh.2010.2696     Document Type: Article

References (62)

1. Winkler UH. The effect of tranexamic acid on the quality of life of women with heavy menstrual bleeding. Eur J Obstet Gynecol Reprod Biol 2001;99:238-243.
2. Population Division, U.S. Census Bureau. Annual estimates of the population by sex and five-year age groups for the United States: April 1, 2000 to July 1, 2007 (NC-Est2007-01). Available at www.census.gov/popest/national/ asrh/NC-EST2007/NC-EST2007-01.xls Accessed May 7, 2009.
3. Liu Z, Doan QV, Blumenthal P, et al. A systematic review evaluating health-related quality of life, work impairment, and health-care costs and utilization in abnormal uterine bleeding. Value Health 2007;10:183-194.
4. Fraser IS, Critchley HO, Munro MG, et al. A process designed to lead to international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding. Fertil Steril 2007;87:466-476.
5. National Collaborating Centre for Women's and Children's Health. Heavy menstrual bleeding. National Institute for Health and Clinical Excellence. London, UK: RCOG Press, 2007:1-164.
6. Shankar M, Chi C, Kadir RA. Review of quality of life: Menorrhagia in women with or without inherited bleeding disorders. Haemophilia 2008;14:15-20.
7. Frick KD, Clark MA, Steinwachs DM, et al. Financial and quality-of-life burden of dysfunctional uterine bleeding among women agreeing to obtain surgical treatment. Wo-mens Health Issues 2009;19:70-78.
8. Cohen BJ, Gibor Y. Anemia and menstrual blood loss. Obstet Gynecol Surv 1980;35:597-618.
9. Morrison J, Patel ST, Watson W, et al. Assessment of the prevalence and impact of anemia on women hospitalized for gynecologic conditions associated with heavy uterine bleeding. J Reprod Med 2008;53:323-330.
10. Nagele F, O'Connor H, Davies A, et al. 2500 outpatient diagnostic hysteroscopies. Obstet Gynecol 1996;88:87-92.
11. Vercellini P, Cortesi I, Oldani S, et al. The role of transvaginal ultrasonography and outpatient diagnostic hystero-scopy in the evaluation of patients with menorrhagia. Hum Reprod 1997;12:1768-7171.
12. Phillip C, Dilley A, Miller C, et al. Platelet functional defects in women with unexplained menorrhagia. J Thromb Hae-most 2003;1:477-484.
13. Shankar M, Lee CA, Sabin CA, et al. Willebrand disease in women with menorrhagia: A systematic review. Br J Obstet Gynaecol 2004;111:734-740.
14. Aberdeen Endometrial Ablation Trials Group. A randomised trial of endometrial ablation versus hysterectomy for the treatment of dysfunctional uterine bleeding: Outcome at four years. Br J Obstet Gynaecol 1999;106:360-366.
15. Marjoribanks J, Lethaby A, Farquhar C. Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database of Systematic Reviews 2005(4)CD003855.
16. Hare AA, Olah KS. Pregnancy following endometrial ablation: A review article. J Obstet Gynaecol 2005;25:108-114.
17. Creatsas G, Cardamakis E, Deligeoroglou E, et al. Tenox-icam versus lynestrenol-ethinyl estradiol treatment of dysfunctional uterine bleeding cases during adolescence. J Pediatr Adolesc Gynecol 1998;11:177-180.
18. Vairojanavong K, Limchitti D, Sasivimolkul V. Clinical trial of the efficacy of mefenamic acid in relief of menorrhagia and/or dysmenorrhoea. J Med Assoc Thai 1983;66:99-105.
19. Andersch B, Milsom I, Rybo G. An objective evaluation of flurbiprofen and tranexamic acid in the treatment of idio-pathic menorrhagia. Acta Obstet Gynecol Scand 1988;67: 645-648.
20. Edlund M, Blomback M, Fried G. Desmopressin in the treatment of menorrhagia in women with no common coagulation factor deficiency but with prolonged bleeding time. Blood Coagul Fibrinolysis 2002;13:225-231.
21. Kouides PA, Byams VR, Philipp CS, et al. Multisite management study of menorrhagia with abnormal laboratory haemostasis: A prospective crossover study of intranasal desmopressin and oral tranexamic acid. Br J Haematol 2009; 145:212-220.
22. Kriplani A, Kulshrestha V, Agarwal N, et al. Role of tra-nexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. J Obstet Gynaecol 2006;26:673-678.
23. Kadir RA, Lee CA, Sabin CA, et al. DDAVP nasal spray for treatment of menorrhagia in women with inherited bleeding disorders: A randomized placebo-controlled crossover study. Haemophilia 2002;8:787-793.
24. Grover V, Usha R, Gupta U, et al. Management of cyclical menorrhagia with prostaglandin synthetase inhibitor. Asia Oceania J Obstet Gynaecol 1990;16:255-259.
25. Callender ST, Warner GT, Cope E. Treatment of menorrha-gia with tranexamic acid. A double-blind trial. BMJ 1970;4: 214-216.
26. Preston JT, Cameron IT, Adams EJ, et al. Comparative study of tranexamic acid and norethisterone in the treatment of ovula-tory menorrhagia. Br J Obstet Gynaecol 1995;102:401-406.
27. Vermylen J, Verhaegen-Declercq ML, Verstraete M, et al. A double blind study of the effect of tranexamic acid in essential menorrhagia. Thromb Diath Haemorrh 1968;20:583-587.
28. Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: Randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. BMJ 1996;313: 579-582.
29. Edlund M, Andersson K, Rybo G, et al. Reduction of menstrual blood loss in women suffering from idiopathic men-orrhagia with a novel antifibrinolytic drug (Kabi 2161). Br J Obstet Gynaecol 1995;102:913-917.
30. Milsom I, Andersson K, Andersch B, et al. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idio-pathic menorrhagia. Am J Obstet Gynecol 1991;164:879-883.
31. Fraser IS, McCarron G. Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia. Aust NZ J Obstet Gynaecol 1991;31: 66-70.
32. Hall P, Maclachlan N, Thorn N, et al. Control of menor-rhagia by the cyclo-oxygenase inhibitors naproxen sodium and mefenamic acid. Br J Obstet Gynaecol 1987;94:554-558.
33. Ylikorkala O, Pekonen F. Naproxen reduces idiopathic but not fibromyoma-induced menorrhagia. Obstet Gynecol 1986; 68:10-12.
34. Rybo G, Nilsson S, Sikstrom B, et al. Naproxen in menor-rhagia. Lancet 1981;1:608-609.
35. Mäkäräinen L, Ylikorkala O. Primary and myoma-associated menorrhagia: Role of prostaglandins and effects of ibuprofen. Br J Obstet Gynaecol 1986;93:974-978.
36. Cameron IT, Haining R, Lumsden MA, et al. The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstet Gynecol 1990;76:85-88.
37. Dockeray CJ, Sheppard BL, Bonnar J. Comparison between mefenamic acid and danazol in the treatment of established menorrhagia. Br J Obstet Gynaecol 1989;96:840-844.
38. Muggeridge J, Elder M. Mefenamic acid in the treatment of menorrhagia. Res Clin Forums 1983;5:83-88.
39. Chamberlain G, Freeman R, Price F, et al. A comparative study of ethamsylate and mefenamic acid in dysfunctional uterine bleeding. Br J Obstet Gynaecol 1991;98:707-711.
40. Harrison RF, Campbell S. A double-blind trial of ethamsy-late in the treatment of primary and intrauterine-device menorrhagia. Lancet 1976;2:283-285.
41. Nilsson L, Rybo G. Treatment of menorrhagia with epsilon aminocaproic acid. A double blind investigation. Acta Obstet Gynecol Scand 1965;44:467-473.
42. Nilsson L, Rybo G. Treatment of menorrhagia with an an-tifibrinolytic agent, tranexamic acid (AMCA). Acta Obstet Gynecol Scand 1967;46:572.
43. van Eijkeren MA, Christiaens GC, Geuze HJ, et al. Effects of mefenamic acid on menstrual hemostasis in essential men-orrhagia. Am J Obstet Gynecol 1992;166:1419-1428.
44. Reid PC, Virtanen-Kari S. Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: A multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts. Br J Obstet Gynaecol 2005;112:1121-1125.
45. Cameron IT, Leask R, Kelly RW, Baird DT. The effects of danazol, mefenamic acid, norethisterone and a progesterone-impregnated coil on endometrial prostaglandin concentrations in women with menorrhagia. Prostaglandins 1987; 34:99-110.
46. Tsang BK, Domingo MT, Spence JE, et al. Endometrial prostaglandins and menorrhagia: Influence of a prosta-glandin synthetase inhibitor in vivo. Can J Physiol Pharmacol 1987;65:2081-2084.
47. Fraser IS, Pearse C, Shearman RP, et al. Efficacy of mefe-namic acid in patients with a complaint of menorrhagia. Obstet Gynecol 1981;58:543-551.
48. Dunn AL, Powers JR, Ribeiro MJ, Rickles FR, Abshire TC. Adverse events during use of intranasal desmopressin acetate for haemophilia A and von Willebrand disease: a case report and review of 40 patients. Haemophilia 2000;6:11-14.
49. Abbott JA, Hawe J, Garry R. Quality of life should be considered the primary outcome for measuring success of endometrial ablation. J Am Assoc Gynecol Laparosc 2003; 10:491-495.
50. Dockeray CJ, Sheppard BL, Daly L, et al. The fibrinolytic enzyme system in normal menstruation and excessive uterine bleeding and the effect of tranexamic acid. Eur J Obstet Gynecol Reprod Biol 1987;24:309-318.
51. Edlund M, Blomback M, He S. On the correlation between local fibrinolytic activity in menstrual fluid and total blood loss during menstruation and effects of desmopressin. Blood Coagul Fibrinolysis 2003;14:593-598.
52. Gleeson N, Devitt M, Sheppard BL, et al. Endometrial fi-brinolytic enzymes in women with normal menstruation and dysfunctional uterine bleeding. Br J Obstet Gynaecol 1993;100:768-771.
53. Dunn CJ, Goa KL. Tranexamic acid: A review of its use in surgery and other indications. Drugs 1999;57:1005-1032.
54. Collen D. Ham-Wasserman Lecture: Role of the plasmino-gen system in fibrin-homeostasis and tissue remodeling. Hematology Am Soc Hematol Educ Program 2001:1-9.
55. Van Eijkeren MA, Christiaens GC, Sixma JJ, et al. Menor-rhagia: A review. Obstet Gynecol Surv 1989;44:421-429.
56. Lethaby A, Farquhar C, Cooke I. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database of Systematic Reviews 2000; CD000249.
57. Philipp CS, Faiz A, Dowling N, et al. Age and the prevalence of bleeding disorders in women with menorrhagia. Obstet Gynecol 2005;105:61-66.
58. Gompels MM, Lock RJ, Abinun M, et al. C1 inhibitor deficiency: Consensus document. Clin Exp Immunol 2005;139: 379-394.
59. Rybo G. Tranexamic acid therapy-Effective treatment in heavy menstrual bleeding. Clinical update on safety. Ther Adv 1991;4:1-8.
60. Garcia Rodriguez LA, Barreales Tolosa L. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastro-enterology 2007;132:498-506.
61. Ong CK, Lirk P, Tan CH, et al. An evidence-based update on nonsteroidal anti-inflammatory drugs. Clin Med Res 2007;5: 19-34.
62. Kouides PA, Kadir RA. Menorrhagia associated with laboratory abnormalities of hemostasis: Epidemiological, diagnostic and therapeutic aspects. J Thromb Haemost 2007;5: 175-182.